Log ind
|
Opret profil
|
Hjælp
Forside
Aktier
Mine porteføljer
Valuta
Webshop
Debat
Nyheder
SaxoTraderGO
Søg
|
Arkiv
|
Mine tråde
|
Filtre
|
Sprog
|
Toplister
|
Retningslinjer
Aktiedebat
Cafe EuroInvestor
Aktiedebat
Cafe EuroInvestor
Sprog
Luk
Filters
Indeksfilter
|
Markedsfilter
|
Aktiefilter
|
Skribentfilter
|
Porteføljeaktier
|
Nyhedsfilter
Luk
OMXC20:
OMXN40:
CAC40:
FTSE100:
S&P500:
NASDAQ100:
DK:
SE:
NO:
US:
GB:
DE:
FR:
Aktiefilteret er
Ændre filter
|
Aktivér
Deaktivér
Skribentfilteret er
Ændre filter
|
Aktivér
Deaktivér
Fjern filtrerede indlæg fra debatten. (Svar på disse indlæg vil også blive fjernet)
Porteføljeaktier:
Denne funktion kræver login
Default watchlist
Demo portefølje
Demo portefølje
Demo portefølje
Demo portefølje
Demo portefølje
Demo portefølje 2
Demo portefølje 3 (i USD)
Demo portfölj
Demoportefølje
Demoportefølje
Nyhedsfilter:
Aktivér nyhedsfilter:
Søgemuligheder
Aktie/Skribent/Tekst
|
Emnenummer
Luk
Aktie:
Søg efter indlæg om en bestemt aktie.
Skribent:
Søg efter indlæg af en bestemt skribent.
Tekst:
Søg efter indlæg med en bestemt tekst.
Dato:
Angiv datointerval for din søgning
Fra dato:
Til dato:
Vis kun indlæg med et positivt antal stemmer i søgningen.
Emnenummer:
Find en tråd ud fra dens nummer
Søg efter indlæg
Forrige side
Næste side
Sanofi vandt ikke frem i retten i USA
<p>En god Novo nyhed</p> <p>&nbsp;</p> <h1 class="entry-title" style="box-sizing: border-box; margin: 0px 0px 10px; font-size: 30px; font-family: Arial, Helvetica, sans-serif; line-height: 1.1; color: #444444; padding: 0px; border: 0px; outline: 0px; vertical-align: baseline; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Novo Gets Sanofi's Insulin Advertising Claims Trimmed</h1> <div id="article-body" style="box-sizing: border-box; margin: 0px; padding: 0px; border: 0px; outline: 0px; font-size: 15px; vertical-align: baseline; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; line-height: 24px; color: #444444; font-family: sans-serif;"> <p class="byline" style="box-sizing: border-box; margin-bottom: 15px; padding: 5px 0px; border-width: 1px 0px; border-top-style: solid; border-right-style: initial; border-bottom-style: solid; border-left-style: initial; border-top-color: #eaeaea; border-right-color: initial; border-bottom-color: #eaeaea; border-left-color: initial; border-image: initial; outline: 0px; font-size: 12px; vertical-align: baseline; background: transparent; line-height: 16px; width: 600px;"><span style="box-sizing: border-box; margin: 0px; padding: 0px; border: 0px; outline: 0px; vertical-align: baseline; background: transparent;">By&nbsp;<strong style="box-sizing: border-box; margin: 0px; padding: 0px; border: 0px; outline: 0px; vertical-align: baseline; background: transparent;"><a id="reporter-popover" style="box-sizing: border-box; background: transparent; color: #00427f; text-decoration-line: none; margin: 0px; padding: 0px; vertical-align: baseline; outline: 0px;" href="https://www.law360.com/search/articles?q=reporter:%22Jeannie%20O%27Sullivan%22">Jeannie O'Sullivan</a></strong></span></p> Law360, New York (July 10, 2017, 4:35 PM EDT) -- A New Jersey federal judge on Monday tossed&nbsp;<a style="box-sizing: border-box; background: transparent; color: #00427f; text-decoration-line: none; margin: 0px; padding: 0px; vertical-align: baseline; outline: 0px;" href="https://www.law360.com/companies/sanofi-aventis">Sanofi-Aventis</a>&rsquo; state consumer fraud law claim against&nbsp;<a style="box-sizing: border-box; background: transparent; color: #00427f; text-decoration-line: none; margin: 0px; padding: 0px; vertical-align: baseline; outline: 0px;" href="https://www.law360.com/companies/novo-nordisk-a-s">Novo Nordisk</a>&nbsp;over allegedly unlawful marketing of its competing diabetes medication, reasoning that the statute aims to protect customers, not competitors.&nbsp;<br style="box-sizing: border-box;" />U.S. District Judge Michael A. Shipp's letter opinion trims without prejudice one of three claims in Sanofi-Aventis U.S. LLC's lawsuit accusing Novo-Nordisk Inc. of using misleading advertising of its long-acting insulin drug Tresiba in order to outsell Sanofi-Aventis' competing diabetes medications, Lantus and Toujeo.<br style="box-sizing: border-box;" /><br style="box-sizing: border-box;" />In granting Novo Nordisk's bid to toss Sanofi-Aventis&rsquo; New Jersey Consumer Fraud Act claim, Judge Shipp invoked a New Jersey federal court&rsquo;s March 2016 decision in Interlink Products International v. F&amp;W Trading, holding that the law isn&rsquo;t intended to protect competitors who haven&rsquo;t suffered a consumer-like injury. The judge rejected Sanofi-Aventis&rsquo; urging that the court reject the reasoning in Interlink.<br style="box-sizing: border-box;" /><br style="box-sizing: border-box;" />Sanofi-Aventis doesn&rsquo;t &ldquo;identify any New Jersey state court, district of New Jersey or Third Circuit decisions issued after Interlink that support plaintiff&rsquo;s position,&rdquo; the opinion said.<br style="box-sizing: border-box;" /><br style="box-sizing: border-box;" />The suit, filed in December, contends Novo Nordisk &ldquo;engaged in a nationwide advertising and promotional campaign for Tresiba that prominently features false and misleading claims about the continued availability of Lantus and Toujeo.&rdquo; In addition to the CFA claim, the three-count complaint also lodged claims of false advertising under the Lanham Act and unfair competition.<br style="box-sizing: border-box;" /><br style="box-sizing: border-box;" />Lantus and Toujeo are both long-acting insulin drugs. Lantus is used to treat adults with Type 2 diabetes and adults and pediatric patients with Type 1 diabetes, while Toujeo is used to treat only adults, the complaint says. Sanofi-Aventis touted Lantus as the world&rsquo;s best-selling insulin brand.<br style="box-sizing: border-box;" /><br style="box-sizing: border-box;" />In August,&nbsp;<a style="box-sizing: border-box; background: transparent; color: #00427f; text-decoration-line: none; margin: 0px; padding: 0px; vertical-align: baseline; outline: 0px;" href="https://www.law360.com/companies/cvs-caremark-corporation">CVS Caremark</a>, the prescription benefit manager for many health insurance providers, announced it would&nbsp; be removing Lantus and Toujeo from its &ldquo;standard formulary,&rdquo; which is a list of list of prescription drugs available to enrollees of a given health insurance plan, the complaint said. The drug store said it would replace the drugs with&nbsp;<a style="box-sizing: border-box; background: transparent; color: #00427f; text-decoration-line: none; margin: 0px; padding: 0px; vertical-align: baseline; outline: 0px;" href="https://www.law360.com/companies/eli-lilly-and-company">Eli Lilly</a>&nbsp;and Co.&rsquo;s Basaglar.<br style="box-sizing: border-box;" /><br style="box-sizing: border-box;" />&ldquo;Millions of individuals&rdquo; would remain unaffected by this change, Sanofi-Aventis contended in its suit. Howeverr, Novo Nordisk allegedly saw this as an opportunity to market Tresiba and then launched a campaign which &ldquo;falsely and misleadingly&rdquo; described the impact of CVS&rsquo;s change, the complaint said.<br style="box-sizing: border-box;" /><br style="box-sizing: border-box;" />For example, Novo Nordisk released an advertisement in September stating that, as of January, Tresiba would be placed on the preferred tier of the CVS formulary and Lantus and Toujeo would be &ldquo;blocked,&rdquo; the complaint said. The ad encouraged patients to contact prescribers to change to Tresiba. Sanofi-Aventis counters that the drug will still be covered, albeit for a higher copay for about 25 percent to 30 percent of consumers subject to the formulary. Remaining consumers will receive co-pay assistance from Sanofi-Aventis or pay-of-pocket.<br style="box-sizing: border-box;" /><br style="box-sizing: border-box;" />Further, the ad is also false and misleading because it suggests that Tresiba, not Basaglar, was the replacement for Lantus and Toujeo on the standard formulary,&nbsp; the complaint said. Novo Nordisk refused to pull the ads despite Sanofi-Aventis' communications throughout September and October, citing &ldquo;serious concern.&rdquo;&nbsp;&nbsp;<br style="box-sizing: border-box;" /><br style="box-sizing: border-box;" />Novo Nordisk was pleased with the ruling and looks forward to proving the remaining claims are "without merit," company spokesman Ken Innchausti told Law360.<br style="box-sizing: border-box;" /><br style="box-sizing: border-box;" />A representative for Sanofi-Aventis didn&rsquo;t immediately respond to requests for comment Monday.<br style="box-sizing: border-box;" /><br style="box-sizing: border-box;" />Sanofi-Aventis US is represented by Cassandra Barbara Roth and David Brian Hennes of Ropes Gray LLP.<br style="box-sizing: border-box;" /><br style="box-sizing: border-box;" />Novo Nordisk is represented by Robert J. Jack and Frank Solano Jr. of&nbsp;&nbsp;<a style="box-sizing: border-box; background: transparent; color: #00427f; text-decoration-line: none; margin: 0px; padding: 0px; vertical-align: baseline; outline: 0px;" href="https://www.law360.com/firms/friedman-kaplan">Friedman Kaplan Seiler &amp; Adelman LLP</a>&nbsp;and Marc De Leeuw of&nbsp;<a style="box-sizing: border-box; background: transparent; color: #00427f; text-decoration-line: none; margin: 0px; padding: 0px; vertical-align: baseline; outline: 0px;" href="https://www.law360.com/firms/sullivan-cromwell">Sullivan &amp; Cromwell LLP</a>.<br style="box-sizing: border-box;" /><br style="box-sizing: border-box;" />The case is Sanofi-Aventis U.S. LLC v. Novo Nordisk Inc., case number&nbsp;<a style="box-sizing: border-box; background: transparent; color: #00427f; text-decoration-line: none; margin: 0px; padding: 0px; vertical-align: baseline; outline: 0px;" href="https://www.law360.com/cases/585d7b075270e86a6f000002">3:16-cv-09466</a>, in U.S. District Court for the District of New Jersey.<br style="box-sizing: border-box;" /><br style="box-sizing: border-box;" />--Editing by Pamela Wilkinson.</div>
Tråde pr. side:
25
50
100
Forrige side
Næste side
Nyt emne
Indlæg af
:
(
Tilføj til skribentfilter
)
Sendt
:
Emne nummer
:
Sprog
:
Vedrørende aktie
:
Emne:
Besvar
Indtast svar:
Opret indlæg
Aktiekurs info
Kurs
+/-
Sidst opdateret
Kurs da dette indlæg blev skrevet
Opret nyt indlæg i debat
Bemærk
: Det er ikke tilladt at benytte mere end ét brugernavn i debatten. Overtrædelse medfører øjeblikkelig udelukkelse.
Initial step - choose language:
Dansk
Engelsk
Svensk
Norsk
Trin 1: Vælg aktie
- Vælg hvilken aktie dit indlæg vedrører - eller gå direkte til trin 2
Så vil du få følgende fordele:
Dit indlæg får automatisk tilføjet link til aktiekursinformationer for den pågældende aktie.
Dit indlæg bliver læst oftere, da det let kan findes ved en aktiesøgning.
Du bidrager positivt til forummet
Trin 2: Overskriften for dit indlæg
Trin 3: Tekst til dit indlæg
Trin 4: Opret overvågning
Opret overvågning på dit indlæg, og du vil modtage en email hver gang dit indlæg besvares.
ADMIN: gør til permanent topindlæg
Opret indlæg
Version: LiveBranchBuild_20170706.1 - EUROWEB2 - 2017-07-12 04:53:49 - 2017-07-12 04:53:49 - 1 - Website: OKAY